Literature DB >> 28755705

Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck.

Aditya V Shetty1, Deborah J Wong2.   

Abstract

In patients with locally advanced squamous cell cancer of the head and neck, a multimodality treatment approach is recommended. The addition of platinum-based systemic therapy concurrently with radiation has been shown to be superior to radiation alone and is considered standard therapy for locally advanced disease. No study has shown superiority of induction therapy followed by chemoradiotherapy versus chemoradiotherapy alone. In the adjuvant setting only patients with nodal extracapsular extension or positive margins seem to benefit from chemoradiotherapy versus radiotherapy alone. In the recurrent or metastatic setting, systemic treatment with chemotherapy is palliative. A subset of patients treated with PD-1 immunotherapy may achieve durable responses. Published by Elsevier Inc.

Entities:  

Keywords:  Chemoradiation; Cisplatin; Erbitux; PD-1 inhibition

Mesh:

Substances:

Year:  2017        PMID: 28755705     DOI: 10.1016/j.otc.2017.03.013

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  4 in total

1.  Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.

Authors:  J Martínez-Trufero; A Lozano Borbalas; I Pajares Bernad; M Taberna Sanz; E Ortega Izquierdo; B Cirauqui Cirauqui; J Rubió-Casadevall; M Plana Serrahima; J M Ponce Ortega; I Planas Toledano; J Caballero; J Marruecos Querol; L Iglesias Docampo; J Lambea Sorrosal; J C Adansa; R Mesía Nin
Journal:  Clin Transl Oncol       Date:  2021-04-19       Impact factor: 3.405

2.  Standardized Diagnostic Workup and Patient-Centered Decision Making for Surgery and Neck Dissection Followed by Risk-Factor Adapted Adjuvant Therapy Improve Loco-Regional Control in Local Advanced Oral Squamous Cell Carcinoma.

Authors:  Gunnar Wichmann; Mykola Pavlychenko; Maria Willner; Dirk Halama; Thomas Kuhnt; Regine Kluge; Tanja Gradistanac; Sandra Fest; Theresa Wald; Bernd Lethaus; Andreas Dietz; Susanne Wiegand; Veit Zebralla
Journal:  Front Oncol       Date:  2021-11-10       Impact factor: 6.244

3.  Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule.

Authors:  Adeline Pêtre; Cécile Dalban; Andy Karabajakian; Eve-Marie Neidhardt; Pierre Eric Roux; Marc Poupart; Sophie Deneuve; Philippe Zrounba; Jérome Fayette
Journal:  Oncotarget       Date:  2018-04-24

4.  KIF18A promotes head and neck squamous cell carcinoma invasion and migration via activation of Akt signaling pathway.

Authors:  Guancheng Liu; Gengming Cai; Xiaosong He; Donghai Huang; Gangcai Zhu; Changhan Chen; Xin Zhang
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.